Chronic myelogenous leukemia epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
The incidence of Chronic Myeloid Leukemia (CML) was estimated to be 1–2 cases per 100,000 individuals worldwide and accounts for 15% of adult leukemias. The peak age for the CML is 50 to 55 and some series report a median age of up to 67 years. incidence in CML increases by age, at least up to 75–80 years and in children, is a very rare disease with an incidence of 0.6–1.2 million children/year. males are more commonly affected with CML than females. The male-to-female ratio varying between 1.2 and 1.7 in different studies. The gender difference in incidence is less prominent in younger people.<ref name="pmid24729196">{{cite journal |vauthors=Jabbour E, Kantarjian H |title=Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management |journal=Am. J. Hematol. |volume=89 |issue=5 |pages=547–56 |date=May 2014 |pmid=24729196 |doi=10.1002/ajh.23691 |url=}}</ref><ref name="pmid20221270">{{cite journal |vauthors=von Bubnoff N, Duyster J |title=Chronic myelogenous leukemia: treatment and monitoring |journal=Dtsch Arztebl Int |volume=107 |issue=7 |pages=114–21 |date=February 2010 |pmid=20221270 |pmc=2835925 |doi=10.3238/arztebl.2010.0114 |url=}}</ref> <ref name="pmid25814090">{{cite journal |vauthors=Höglund M, Sandin F, Simonsson B |title=Epidemiology of chronic myeloid leukaemia: an update |journal=Ann. Hematol. |volume=94 Suppl 2 |issue= |pages=S241–7 |date=April 2015 |pmid=25814090 |doi=10.1007/s00277-015-2314-2 |url=}}</ref><ref name="pmid10428738">{{cite journal |vauthors=Faderl S, Talpaz M, Estrov Z, Kantarjian HM |title=Chronic myelogenous leukemia: biology and therapy |journal=Ann. Intern. Med. |volume=131 |issue=3 |pages=207–19 |date=August 1999 |pmid=10428738 |doi= |url=}}</ref> | The incidence of Chronic Myeloid Leukemia (CML) was estimated to be 1–2 cases per 100,000 individuals worldwide and accounts for 15% of adult leukemias. The peak age for the CML is 50 to 55 and some series report a median age of up to 67 years. incidence in CML increases by age, at least up to 75–80 years and in children, is a very rare disease with an incidence of 0.6–1.2 million children/year. males are more commonly affected with CML than females. The male-to-female ratio varying between 1.2 and 1.7 in different studies. The gender difference in incidence is less prominent in younger people.<ref name="pmid24729196">{{cite journal |vauthors=Jabbour E, Kantarjian H |title=Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management |journal=Am. J. Hematol. |volume=89 |issue=5 |pages=547–56 |date=May 2014 |pmid=24729196 |doi=10.1002/ajh.23691 |url=}}</ref><ref name="pmid20221270">{{cite journal |vauthors=von Bubnoff N, Duyster J |title=Chronic myelogenous leukemia: treatment and monitoring |journal=Dtsch Arztebl Int |volume=107 |issue=7 |pages=114–21 |date=February 2010 |pmid=20221270 |pmc=2835925 |doi=10.3238/arztebl.2010.0114 |url=}}</ref><ref name="pmid25814090">{{cite journal |vauthors=Höglund M, Sandin F, Simonsson B |title=Epidemiology of chronic myeloid leukaemia: an update |journal=Ann. Hematol. |volume=94 Suppl 2 |issue= |pages=S241–7 |date=April 2015 |pmid=25814090 |doi=10.1007/s00277-015-2314-2 |url=}}</ref><ref name="pmid10428738">{{cite journal |vauthors=Faderl S, Talpaz M, Estrov Z, Kantarjian HM |title=Chronic myelogenous leukemia: biology and therapy |journal=Ann. Intern. Med. |volume=131 |issue=3 |pages=207–19 |date=August 1999 |pmid=10428738 |doi= |url=}}</ref> | ||
==Epidemiology== | ==Epidemiology== | ||
Revision as of 14:37, 31 July 2018
|
Chronic myelogenous leukemia Microchapters |
|
Differentiating Chronic myelogenous leukemia from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Chronic myelogenous leukemia epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Chronic myelogenous leukemia epidemiology and demographics |
|
FDA on Chronic myelogenous leukemia epidemiology and demographics |
|
CDC on Chronic myelogenous leukemia epidemiology and demographics |
|
Chronic myelogenous leukemia epidemiology and demographics in the news |
|
Blogs on Chronic myelogenous leukemia epidemiology and demographics |
|
Directions to Hospitals Treating Chronic myelogenous leukemia |
|
Risk calculators and risk factors for Chronic myelogenous leukemia epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]
Overview
The incidence of Chronic Myeloid Leukemia (CML) was estimated to be 1–2 cases per 100,000 individuals worldwide and accounts for 15% of adult leukemias. The peak age for the CML is 50 to 55 and some series report a median age of up to 67 years. incidence in CML increases by age, at least up to 75–80 years and in children, is a very rare disease with an incidence of 0.6–1.2 million children/year. males are more commonly affected with CML than females. The male-to-female ratio varying between 1.2 and 1.7 in different studies. The gender difference in incidence is less prominent in younger people.[1][2][3][4]
Epidemiology
Incidence
- [5]1–2 cases per 100,000
Age
- peak age for the CML is 50 to 55
Gender
- [5]males are more commonly affected with CML than females
References
- ↑ Jabbour E, Kantarjian H (May 2014). "Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management". Am. J. Hematol. 89 (5): 547–56. doi:10.1002/ajh.23691. PMID 24729196.
- ↑ von Bubnoff N, Duyster J (February 2010). "Chronic myelogenous leukemia: treatment and monitoring". Dtsch Arztebl Int. 107 (7): 114–21. doi:10.3238/arztebl.2010.0114. PMC 2835925. PMID 20221270.
- ↑ Höglund M, Sandin F, Simonsson B (April 2015). "Epidemiology of chronic myeloid leukaemia: an update". Ann. Hematol. 94 Suppl 2: S241–7. doi:10.1007/s00277-015-2314-2. PMID 25814090.
- ↑ Faderl S, Talpaz M, Estrov Z, Kantarjian HM (August 1999). "Chronic myelogenous leukemia: biology and therapy". Ann. Intern. Med. 131 (3): 207–19. PMID 10428738.
- ↑ 5.0 5.1 Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z,Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.